A9920
β-Alanine
BioReagent, suitable for cell culture, suitable for insect cell culture
Synonym(s):
β-Ala, 3-Aminopropionic acid
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Linear Formula:
NH2CH2CH2COOH
CAS Number:
Molecular Weight:
89.09
NACRES:
NA.75
PubChem Substance ID:
eCl@ss:
39030936
UNSPSC Code:
12352209
EC Number:
203-536-5
MDL number:
Beilstein/REAXYS Number:
906793
product line
BioReagent
Quality Level
assay
≥98% (TLC)
form
powder or crystals
technique(s)
cell culture | insect: suitable, cell culture | mammalian: suitable
color
white
mp
202 °C (dec.) (lit.)
InChI
1S/C3H7NO2/c4-2-1-3(5)6/h1-2,4H2,(H,5,6)
InChI key
UCMIRNVEIXFBKS-UHFFFAOYSA-N
General description
An N-blocked form of alanine.
Biochem/physiol Actions
Endogenous β-amino acid that is a nonselective agonist at glycine receptors and a ligand for the G protein-coupled orphan receptor, TGR7 (MrgD). β-Alanine is a component of pantothenic acid.
β-Alanine, a β−amino acid, is a component of pantothenic acid and the rate-limiting amino acid in the biosynthesis of the histidinyl antioxidant dipeptides carnosine and anserine. Endogenous β-amino acid that is a nonselective agonist at glycine receptors and a ligand for the G protein-coupled orphan receptor, TGR7 (MrgD). β-Alanine flux plays a cytoprotective role by supporting the osmotic stability of marine organisms, preimplantation mouse embryos and mammalian cells exposed to hypoxic stress.
Still not finding the right product?
Explore all of our products under β-Alanine
Storage Class
13 - Non Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Ramin Artang et al.
The American journal of cardiology, 112(12), 1973-1979 (2013-10-01)
Dabigatran has been associated with greater risk of myocardial infarction (MI) than warfarin. It is unknown whether the increased risk is unique to dabigatran, an adverse effect shared by other oral direct thrombin inhibitors (DTIs), or the result of a
Wilma Potze et al.
British journal of haematology, 163(5), 666-673 (2013-11-14)
There is increasing recognition that thrombotic complications may occur in patients with cirrhosis, and literature on antithrombotic treatment in these patients is rapidly emerging. Due to extensive haemostatic changes in patients with cirrhosis, careful monitoring of anticoagulant therapy may be
Torben Bjerregaard Larsen et al.
The American journal of medicine, 127(4), 329-336 (2013-12-24)
Dabigatran may provide less protection against myocardial infarction than vitamin K antagonists (VKAs) in patients with atrial fibrillation. This may be particularly evident among "switchers" to dabigatran from VKA, as a result of discontinuation effects. We identified in nationwide Danish